Dr. Vivek Narayan, a medical oncologist at the University of Pennsylvania, shares the latest in prostate cancer treatment advances.
Facing advanced prostate cancer can be a daunting process that brings out many questions and concerns, yet there have been some incredible developments in treating the disease.
Here, Dr. Vivek Narayan, a medical oncologist at the University of Pennsylvania, walks us through some of those developments and advances that are leading to better quality of life and outcomes today.
Content independently created by SurvivorNet with support from Novartis Pharmaceuticals Corp.
Dr. Vivek Narayan
University of Pennsylvania
A diagnosis of metastatic prostate cancer can feel overwhelming. Still, there’s growing hope thanks to new and evolving treatments that can make the cancer manageable and treated more like a chronic disease.
Dr. Vivek Narayan
University of Pennsylvania
Hormone therapy, also called androgen deprivation therapy (ADT), is the initial treatment for metastatic prostate cancer patients, which occurs when the disease spreads beyond the prostate to areas like bones and lymph nodes.
Dr. Vivek Narayan
University of Pennsylvania
Combination therapy — pairing androgen deprivation therapy (ADT) with FDA-approved oral agents — has become a widely used approach for treating metastatic prostate cancer, showing improved outcomes and extended survival.
Dr. Vivek Narayan
University of Pennsylvania
Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells, delivering systemic radiation that minimizes harm to healthy tissue.
Sign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.
